Hilleman Lab to invest Rs 300 crore to develop vaccines
Mumbai: Hilleman Laboratories today said it will invest around Rs 300 crore in the next 4-5 years to develop low-cost vaccines to treat diseases like cholera and meningitis.The company is a 50:50 joint venture between MSD Pharmaceuticals and UK-based Wellcome Trust."We are spending around Rs 300 crore over the next 4-5 years to develop low-cost vaccines. We are developing vaccines to...
Login or Register to read the full article
Mumbai: Hilleman Laboratories today said it will invest around Rs 300 crore in the next 4-5 years to develop low-cost vaccines to treat diseases like cholera and meningitis.
The company is a 50:50 joint venture between MSD Pharmaceuticals and UK-based Wellcome Trust.
"We are spending around Rs 300 crore over the next 4-5 years to develop low-cost vaccines. We are developing vaccines to treat rotavirus, cholera and meningitis," Hilleman lab CEO Davinder Gill told here.
"For research, we are looking for partners namely pharma companies, vaccine speciality companies and Government agencies to collaborate and fund the project. We had received foundational grants from MSD Pharmaceuticals and Wellcome Trust, but now we wants to be financially independent," he said.
MSD Pharmaceuticals and Wellcome Trust invested around Rs 700 crore nearly five years ago in the company which is now valued at around Rs 900 crore, he added.
MSD Pharmaceuticals (also known as Merck Sharp & Dohme or MSD in many parts of the world) is an affiliate of Merck & Co Inc.
"Normally, there is a large capital investment required for creating vaccines. We, however, have taken an approach that will allow the vaccines to be created at a lesser cost thus providing a boost to manufacturers, who can use synthetic platform technology," Gill said.
The company is developing a synthetic vaccine to fight meningitis in Asian, African and Latin American countries.
"We are developing a vaccine for rotavirus, which would be heat-resistant and easy to carry. We have already started clinical trials and it will be ready in 3-4 years," Gill said.
As per the development plan, Medicine in Need, a not- for-profit research organisation, will make available the company its formulation technology, while MSD would provide components of its existing rotavirus vaccine, he added. AP RSY MKJ
The company is a 50:50 joint venture between MSD Pharmaceuticals and UK-based Wellcome Trust.
"We are spending around Rs 300 crore over the next 4-5 years to develop low-cost vaccines. We are developing vaccines to treat rotavirus, cholera and meningitis," Hilleman lab CEO Davinder Gill told here.
"For research, we are looking for partners namely pharma companies, vaccine speciality companies and Government agencies to collaborate and fund the project. We had received foundational grants from MSD Pharmaceuticals and Wellcome Trust, but now we wants to be financially independent," he said.
MSD Pharmaceuticals and Wellcome Trust invested around Rs 700 crore nearly five years ago in the company which is now valued at around Rs 900 crore, he added.
MSD Pharmaceuticals (also known as Merck Sharp & Dohme or MSD in many parts of the world) is an affiliate of Merck & Co Inc.
"Normally, there is a large capital investment required for creating vaccines. We, however, have taken an approach that will allow the vaccines to be created at a lesser cost thus providing a boost to manufacturers, who can use synthetic platform technology," Gill said.
The company is developing a synthetic vaccine to fight meningitis in Asian, African and Latin American countries.
"We are developing a vaccine for rotavirus, which would be heat-resistant and easy to carry. We have already started clinical trials and it will be ready in 3-4 years," Gill said.
As per the development plan, Medicine in Need, a not- for-profit research organisation, will make available the company its formulation technology, while MSD would provide components of its existing rotavirus vaccine, he added. AP RSY MKJ
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd